Affiliation: University of Calgary
- Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tractOtto Rorstad
Department of Medicine, University of Calgary, Calgary, Alberta, Canada
J Surg Oncol 89:151-60. 2005..Adverse clinical indicators are the malignant carcinoid syndrome, carcinoid heart disease, and high concentrations of the tumor markers, urinary 5-HIAA and plasma chromogranin A...
- Cognitive impairment associated with carcinoid syndromeJanice L Pasieka
Department of Surgery, Division of General Surgery and Surgical Oncology, University of Calgary and Tom Baker Cancer Center, Calgary, Alberta, Canada Department of Medicine, Division of Endocrinology, University of Calgary and Tom Baker Cancer Center, Calgary, Alberta, Canada and Department of Psychology, Foothills Hospital, Calgary, Alberta, Canada
Ann Surg 259:355-9. 2014..To evaluate the cognitive performance of patients with carcinoid syndrome (CS) compared with population norms and cancer patients with non-neuroendocrine (non-NET) liver metastases...
- Role of imaging in the preoperative staging of small bowel neuroendocrine tumorsAnthony J Chambers
Department of Surgery, Division of Surgical Oncology, University of Calgary and the Tom Baker Cancer Centre, Calgary, Alberta, Canada
J Am Coll Surg 211:620-7. 2010..The purpose of this study was to assess the accuracy of preoperative imaging compared with operative findings in the staging of small bowel NET...
- The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumorsAnthony J Chambers
University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Surgery 144:645-51; discussion 651-3. 2008..The purpose of this study was to assess whether aggressive surgical intervention of metastatic NETs provides effective palliation from these symptoms...
- Impairment of cognitive function reported by patients suffering from carcinoid syndromeAnthony J Chambers
Divisions of Surgical Oncology and General Surgery, Department of Surgery, University of Calgary and Tom Baker Cancer Centre, Calgary, AB, T2N 2T9, Canada
World J Surg 34:1356-60. 2010..It has been our impression that patients with CS also exhibit features of cognitive impairment. The purpose of this pilot study was to evaluate if symptoms of cognitive impairment were reported by patients with CS...
- The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasmsJanice L Pasieka
Division of General Surgery, Department of Surgery, North Tower, University of Calgary and Tom Baker Cancer Center, 1403 29th Street NW, Calgary, Alberta, Canada T2N 2T9
Surgery 136:1218-26. 2004..Radiolabeled octreotide and metaiodobenzylguanidine (MIBG) have demonstrated limited antitumor effect on neuroendocrine neoplasms (NENs). The purpose of this study was to assess the palliative benefit of radionuclide therapy (RNT) in NENs...
- 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumorsMark S Sywak
Royal North Shore Hospital, St Leonards, New South Wales, Australia
World J Surg 28:1157-62. 2004..6 years for group A and 5.0 years for group B. Although retrospective in nature, this study suggests that the addition of 131I-mIBG therapy to the treatment protocol of patients with metastatic midgut carcinoid tumors prolongs survival...